Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)

Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, Atul Deodhar

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article “Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results,” written by Laura C. Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar, was originally published electronically on the publisher’s internet portal on 16 May 2019 without open access.

Original languageEnglish (US)
JournalClinical Rheumatology
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Clinical Rheumatology, (2022), 10.1007/s10067-022-06218-8)'. Together they form a unique fingerprint.

Cite this